Alpidem

Alpidem
Clinical data
Trade names	Ananxyl
Other names	SL 80.0342; SL800342; SL-800342
Routes of; administration	Oral administration
Drug class	Nonbenzodiazepine; GABAA receptor positive allosteric modulator; Anxiolytic
ATC code	None;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	32–35% (estimated)
Protein binding	99.4%
Metabolism	Extensive (hydroxylation, dealkylation, conjugation)
Metabolites	Many (some active)
Onset of action	1.0–2.5 hours (Cmax)
Elimination half-life	Young adults: 19 hours (7–44 hours); Elderly: 22.6 ± 2.3 hours; Children: 11.4 ± 1.9 hours
Excretion	Mainly feces
Identifiers
	IUPAC name 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide;
CAS Number	82626-01-5 ;
PubChem CID	54897;
ChemSpider	49570 ;
UNII	I93SC245QZ;
KEGG	D02833 ;
ChEBI	CHEBI:135649;
ChEMBL	ChEMBL54349 ;
CompTox Dashboard (EPA)	DTXSID8049046 ;
ECHA InfoCard	100.216.305
Chemical and physical data
Formula	C21H23Cl2N3O
Molar mass	404.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl;
	InChI InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3 ; Key:JRTIDHTUMYMPRU-UHFFFAOYSA-N ;
	(verify)

Alpidem, sold under the brand name Ananxyl, is a nonbenzodiazepine anxiolytic medication which was briefly used to treat anxiety disorders but is no longer marketed. It was previously marketed in France, but was discontinued due to liver toxicity. Alpidem is taken by mouth.

Side effects of alpidem include sedation, fatigue, dizziness, and headache, among others. It has much less to no impact on cognition, memory, and psychomotor function relative to benzodiazepines. Similarly, no rebound anxiety or withdrawal symptoms have been observed with alpidem. Rarely, alpidem can cause serious liver toxicity, including liver failure and death. Alpidem is a nonbenzodiazepine of the imidazopyridine family, structurally related to the Z-drug zolpidem, and acts as a GABA_A receptor positive allosteric modulator of the benzodiazepine site of the receptor complex. In contrast to zolpidem however, alpidem has anxiolytic effects rather than sedative or hypnotic effects at normal therapeutic doses.

Alpidem was first described by 1982 and was introduced for medical use in France in 1991. It was also under development for use in other countries in the 1990s, but development was discontinued and the drug was never marketed in any other country. Alpidem was withdrawn from the market in France in 1993 due to liver toxicity.